Emerging pharmacotherapies for COVID-19.
Identifieur interne : 001689 ( Main/Corpus ); précédent : 001688; suivant : 001690Emerging pharmacotherapies for COVID-19.
Auteurs : Rachana Salvi ; Panini PatankarSource :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [ 1950-6007 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (pharmacology), Antimalarials (pharmacology), Antiviral Agents (pharmacology), Betacoronavirus (drug effects), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (virology), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (etiology), Drug Discovery (methods), Drug Repositioning (methods), Humans (MeSH), Immunologic Factors (pharmacology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , pharmacology : Anti-Inflammatory Agents, Antimalarials, Antiviral Agents, Immunologic Factors.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Pneumonia, Viral.
- etiology : Cytokine Release Syndrome.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- methods : Drug Discovery, Drug Repositioning.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.
DOI: 10.1016/j.biopha.2020.110267
PubMed: 32410772
PubMed Central: PMC7221369
Links to Exploration step
pubmed:32410772Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging pharmacotherapies for COVID-19.</title><author><name sortKey="Salvi, Rachana" sort="Salvi, Rachana" uniqKey="Salvi R" first="Rachana" last="Salvi">Rachana Salvi</name><affiliation><nlm:affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India.</nlm:affiliation></affiliation></author><author><name sortKey="Patankar, Panini" sort="Patankar, Panini" uniqKey="Patankar P" first="Panini" last="Patankar">Panini Patankar</name><affiliation><nlm:affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India. Electronic address: dr.panini1992@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32410772</idno><idno type="pmid">32410772</idno><idno type="doi">10.1016/j.biopha.2020.110267</idno><idno type="pmc">PMC7221369</idno><idno type="wicri:Area/Main/Corpus">001689</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001689</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging pharmacotherapies for COVID-19.</title><author><name sortKey="Salvi, Rachana" sort="Salvi, Rachana" uniqKey="Salvi R" first="Rachana" last="Salvi">Rachana Salvi</name><affiliation><nlm:affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India.</nlm:affiliation></affiliation></author><author><name sortKey="Patankar, Panini" sort="Patankar, Panini" uniqKey="Patankar P" first="Panini" last="Patankar">Panini Patankar</name><affiliation><nlm:affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India. Electronic address: dr.panini1992@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title><idno type="eISSN">1950-6007</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (pharmacology)</term><term>Antimalarials (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (virology)</term><term>Cytokine Release Syndrome (drug therapy)</term><term>Cytokine Release Syndrome (etiology)</term><term>Drug Discovery (methods)</term><term>Drug Repositioning (methods)</term><term>Humans (MeSH)</term><term>Immunologic Factors (pharmacology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (virology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term><term>Drug Repositioning</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32410772</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Emerging pharmacotherapies for COVID-19.</ArticleTitle><Pagination><MedlinePgn>110267</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(20)30459-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2020.110267</ELocationID><Abstract><AbstractText>Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.</AbstractText><CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Rachana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patankar</LastName><ForeName>Panini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India. Electronic address: dr.panini1992@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32410772</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2020.110267</ArticleId><ArticleId IdType="pii">S0753-3322(20)30459-5</ArticleId><ArticleId IdType="pmc">PMC7221369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2003 Jun;111(11):1605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12782660</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 31;34(2):333-338</Citation><ArticleIdList><ArticleId IdType="pubmed">32228825</ArticleId></ArticleIdList></Reference><Reference><Citation>ACR Open Rheumatol. 2020 May;2(5):276-282</Citation><ArticleIdList><ArticleId IdType="pubmed">32267081</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chin Med Assoc. 2020 Jun;83(6):534-536</Citation><ArticleIdList><ArticleId IdType="pubmed">32243270</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343</Citation><ArticleIdList><ArticleId IdType="pubmed">32253888</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation><ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Int. 2020 May;40(5):825-826</Citation><ArticleIdList><ArticleId IdType="pubmed">32232552</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246</Citation><ArticleIdList><ArticleId IdType="pubmed">32247211</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2018 Jan;281(1):191-196</Citation><ArticleIdList><ArticleId IdType="pubmed">29247986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2020 Jul;111:102452</Citation><ArticleIdList><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001689 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001689 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32410772
|texte= Emerging pharmacotherapies for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32410772" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |